
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q One of my patients is an 11-year-old boy diagnosed with mild mental retardation who, his mother says, is very hard to discipline.






